Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Antonio Abbate and Nicola Potere.
Antonio Abbate
Connection Strength
1.650
Nicola Potere
  1. Use of placebo in clinical trials in COVID-19 pandemic times: considerations on pros, cons, challenges and limitations. Minerva Med. 2021 Jul 16.
    View in: PubMed
    Score: 0.239
  2. The role of IL-6 and IL-6 blockade in COVID-19. Expert Rev Clin Immunol. 2021 06; 17(6):601-618.
    View in: PubMed
    Score: 0.237
  3. Response to: 'Correspondence on 'Interleukin-6 blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study' by Potere et al' by Buckley. Ann Rheum Dis. 2020 Sep 01.
    View in: PubMed
    Score: 0.225
  4. Low-dose subcutaneous tocilizumab to prevent disease progression in patients with moderate COVID-19 pneumonia and hyperinflammation. Int J Infect Dis. 2020 Nov; 100:421-424.
    View in: PubMed
    Score: 0.224
  5. Response to: 'Rational use of tocilizumab in COVID-19' by Jain and Sharma. Ann Rheum Dis. 2020 Jul 31.
    View in: PubMed
    Score: 0.224
  6. Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study. Ann Rheum Dis. 2021 02; 80(2):1-2.
    View in: PubMed
    Score: 0.223
  7. Acute complications and mortality in hospitalized patients with coronavirus disease 2019: a systematic review and meta-analysis. Crit Care. 2020 Jul 02; 24(1):389.
    View in: PubMed
    Score: 0.223
  8. Canakinumab in a subgroup of patients with COVID-19. Lancet Rheumatol. 2020 Aug; 2(8):e457-ee458.
    View in: PubMed
    Score: 0.055
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.